Merck (MRK) Change in Receivables (2009)

Merck (MRK) posted quarterly Change in Receivables of $14.0 million for Q4 2009, down 88.71% sequentially from $124.0 million in Q3 2009.

Merck (MRK) Change in Receivables (2009) Analysis & Trends

Merck has disclosed Change in Receivables across 1 years of filings, most recently posting $14.0 million for Q4 2009.

In Q4 2009, Change in Receivables changed N/A year-over-year to $14.0 million; the TTM figure through Dec 2009 stood at $1.4 billion (changed N/A YoY), while the FY2025 annual figure was $1.1 billion, up 346.72% from the prior year.
Change in Receivables fell to $14.0 million in Q4 2009, from $124.0 million in the prior quarter.
Over the last five years, Change in Receivables for MRK reached as high as $124.0 million in Q3 2009 and fell as low as $14.0 million in Q4 2009.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change Receivables (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn	-
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn	595.00 Mn
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn	-87.00 Mn
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn	-
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn	-
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn	-413.00 Mn
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn	-134.00 Mn
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn	-
9	Novartis Ag	113.45 Bn	113.67 Bn	-	-
10	Biogen	30.87 Bn	26.59 Bn	1.82 Bn	-103.40 Mn

Download Data